Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2022 edition).
10.3760/cma.j.cn112152-20220614-00416
- Collective Name:Society of Cancer Precision Medicine of Chinese Anti-Cancer Association;Lung Cancer Expert Group of Chinese Medical Journal
- Publication Type:Journal Article
- Keywords:
Expert consensus;
Immunotherapy;
Lung neoplasms;
Oncogenic driver mutation;
Resistance to targeted therapy
- MeSH:
Humans;
Lung Neoplasms/pathology*;
Carcinoma, Non-Small-Cell Lung/drug therapy*;
Consensus;
Immunotherapy;
Carcinogenesis;
Mutation;
China;
Tumor Microenvironment
- From:
Chinese Journal of Oncology
2022;44(10):1047-1065
- CountryChina
- Language:Chinese
-
Abstract:
Non-small cell lung cancer (NSCLC) with oncogenic driver mutations was previously deemed " forbidden territory" for immunotherapy. With the growing understanding of the impact of target drugs on the immune microenvironment and the continuous generation of clinical evidence, immunotherapy is expected to bring new hope for the NSCLC patients with oncogenic driver mutations. An expert panel of medical oncology, respiratory medicine and pathology organized by the Society of Cancer Precision Medicine of Chinese Anti-Cancer Association and Expert Group on Lung Cancer of Chinese Medical Journal conducted an in-depth discussion on current evidence of immune microenvironment and clinical studies and formulated a Chinese expert consensus on immunotherapy for advanced NSCLC with oncogenic driver mutations by combining with clinical experience. This expert consensus aims to provide guidance for Chinese clinicians on immunotherapy in NSCLC with oncogenic driver mutations.
